| Meghan Marie Hollier, PMHNP | |
|
1018 Chase Dr, Johnson City, TN 37604-1402 | |
| (423) 282-3379 | |
| (423) 430-6227 |
| Full Name | Meghan Marie Hollier |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 1018 Chase Dr, Johnson City, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003410523 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | APN0000027502 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catalyst Health Solutions,llc | 0749615672 | 8 |
| Catalyst Health Solutions,llc | 0749615672 | 8 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In studies examining the risk of adverse outcomes after receipt of the influenza A(H1N1) vaccine, infants exposed to the vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction; while in another, study researchers found a small increased risk in adults of the nervous system disorder, Guillain-Barre syndrome, during the 4 to 8 weeks after vaccination, according to 2 studies in the July 11 issue of JAMA.
A single corticosteroid injection in the wrist can offer at least a month of relief to people suffering from severe carpal tunnel syndrome, according to an updated review of studies by Canadian researchers.
Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.
A new type of CT scan initially costs slightly less than the traditional stress test to diagnose blocked coronary arteries in patients with chest pain, but its lower cost did not translate into medical care savings over time, according to an analysis by Duke Medicine researchers.
› Verified 3 days ago
| Entity Name | Catalyst Health Solutions,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184150229 PECOS PAC ID: 0749615672 Enrollment ID: O20200122002466 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In studies examining the risk of adverse outcomes after receipt of the influenza A(H1N1) vaccine, infants exposed to the vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction; while in another, study researchers found a small increased risk in adults of the nervous system disorder, Guillain-Barre syndrome, during the 4 to 8 weeks after vaccination, according to 2 studies in the July 11 issue of JAMA.
A single corticosteroid injection in the wrist can offer at least a month of relief to people suffering from severe carpal tunnel syndrome, according to an updated review of studies by Canadian researchers.
Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.
A new type of CT scan initially costs slightly less than the traditional stress test to diagnose blocked coronary arteries in patients with chest pain, but its lower cost did not translate into medical care savings over time, according to an analysis by Duke Medicine researchers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meghan Marie Hollier, PMHNP 1018 Chase Dr, Johnson City, TN 37604-1402 Ph: (423) 282-3379 | Meghan Marie Hollier, PMHNP 1018 Chase Dr, Johnson City, TN 37604-1402 Ph: (423) 282-3379 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In studies examining the risk of adverse outcomes after receipt of the influenza A(H1N1) vaccine, infants exposed to the vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction; while in another, study researchers found a small increased risk in adults of the nervous system disorder, Guillain-Barre syndrome, during the 4 to 8 weeks after vaccination, according to 2 studies in the July 11 issue of JAMA.
A single corticosteroid injection in the wrist can offer at least a month of relief to people suffering from severe carpal tunnel syndrome, according to an updated review of studies by Canadian researchers.
Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.
A new type of CT scan initially costs slightly less than the traditional stress test to diagnose blocked coronary arteries in patients with chest pain, but its lower cost did not translate into medical care savings over time, according to an analysis by Duke Medicine researchers.
› Verified 3 days ago
Amber Ramsey, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 119 Boone Ridge Dr, Suite 201, Johnson City, TN 37615 Phone: 423-282-1480 Fax: 423-928-1353 | |
Connie T Rutledge, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 301 Med Tech Pkwy Ste 240, Johnson City, TN 37604 Phone: 423-794-5520 Fax: 423-282-6940 | |
Charity Helton, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 325 N. State Of Franklin Road, Ground Fl, Johnson City, TN 37604 Phone: 423-439-7320 | |
Michael David Smith, NURSE PRACTITIONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3019 Peoples St # Condo300, Johnson City, TN 37604 Phone: 423-461-2100 Fax: 423-461-2199 | |
Shelly J Mcintosh, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 301 Med Tech Pkwy, Suite 240, Johnson City, TN 37604 Phone: 423-794-5520 Fax: 423-282-0720 | |
Miss Samantha Manuel I, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1021 W Oakland Ave, Suite 301, Johnson City, TN 37604 Phone: 423-952-8000 Fax: 423-952-8001 |